Pharma in China will face reduced investor confidence
UK drugmaker AstraZeneca’s China president faces a probe
You must be signed in to read this analysis
In this article
- Data governance
- Licensing and distribution
- Arbitrary probes
What is this?
This article is from the Oxford Analytica Daily Brief, which analyses geopolitical, economic, social, business and industrial developments on a global and regional basis, providing clients with timely, authoritative analysis every business day of the year. Find out more about the Oxford Analytica Daily Brief, or request a trial.
